{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:31:01Z","timestamp":1784172661785,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Generalized vitiligo is an autoimmune disease characterized by melanocyte loss, which results in patchy depigmentation of skin and hair. Recent studies suggested the key role of CD8<jats:sup>+<\/jats:sup>T lymphocytes for mediating immune response in vitiligo through melanocyte differentiation antigens, including tyrosinase, gp100 and MelanA\/Mart-1. However, the specific epitopes of these auto-antigens are still unknown. In our study, we predicted the possible HLA-A*0201-restricted nonapeptides overlaying the full-length amino acid sequences of these three known antigens and investigated the lymphocytes reactivity to these nonapeptides by Elispot assay. In addition, we evaluated the abilities of these nonapeptides to activate CD8<jats:sup>+<\/jats:sup>T cells. We screened out 5 possible epitopes originated from tyrosinase and gp100, numbered P28, P41, P112, P118 and P119. Among these 5 epitopes, notably, P28 and P119 played the dominant role in activating CTLs, with a significant increase in proliferation rate and Interferon-\u03b3 (IFN-\u03b3) production of CD8<jats:sup>+<\/jats:sup>T cells. Nevertheless, antigen-specific T cell reactivity was not detected in MelanA\/Mart-1 peptides. Our studies identified two novel epitopes originated from proteins of gp100 and tyrosinase, which may have implications for the development of immunotherapies for vitiligo.<\/jats:p>","DOI":"10.1038\/srep36360","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T09:33:34Z","timestamp":1478597614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients"],"prefix":"10.1038","volume":"6","author":[{"given":"Tingting","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"BFsrep36360_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1468-3083.2010.03808.x","volume":"25","author":"KY Wang","year":"2011","unstructured":"Wang, K. Y., Wang, K. H. & Zhang, Z. P. Health-related quality of life and marital quality of vitiligo patients in China. J Eur Acad Dermatol Venereol 25, 429\u2013435 (2011).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"BFsrep36360_CR2","doi-asserted-by":"publisher","first-page":"631927","DOI":"10.1155\/2015\/631927","volume":"2015","author":"R Colucci","year":"2015","unstructured":"Colucci, R., Dragoni, F. & Moretti, S. Oxidative stress and immune system in vitiligo and thyroid diseases. Oxid Med Cell Longev 2015, 631927 (2015).","journal-title":"Oxid Med Cell Longev"},{"key":"BFsrep36360_CR3","doi-asserted-by":"publisher","first-page":"13542","DOI":"10.1038\/srep13542","volume":"5","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. AHR promoter variant modulates its transcription and downstream effectors by allele-specific AHR-SP1 interaction functioning as a genetic marker for vitiligo. Sci Rep 5, 13542 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep36360_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/exd.12810","volume":"24","author":"L Machado do Nascimento","year":"2015","unstructured":"Machado do Nascimento, L., Silva de Castro, C. C., Medeiros Fava, V., Iani Werneck, R. & Tavora Mira, M. Genetic and biochemical evidence implicates the butyrylcholinesterase gene BCHE in vitiligo pathogenesis. Exp Dermatol 24, 976\u2013978 (2015).","journal-title":"Exp Dermatol"},{"key":"BFsrep36360_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1600-0749.2007.00408.x","volume":"20","author":"MR Namazi","year":"2007","unstructured":"Namazi, M. R. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected? Pigment Cell Res 20, 360\u2013363 (2007).","journal-title":"Pigment Cell Res"},{"key":"BFsrep36360_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cei.12096","volume":"173","author":"S Sanchez-Sosa","year":"2013","unstructured":"Sanchez-Sosa, S., Aguirre-Lombardo, M., Jimenez-Brito, G. & Ruiz-Arguelles, A. Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo. Clin Exp Immunol 173, 179\u2013183 (2013).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep36360_CR7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/pcmr.12105","volume":"26","author":"M Dwivedi","year":"2013","unstructured":"Dwivedi, M., Laddha, N. C., Arora, P., Marfatia, Y. S. & Begum, R. Decreased regulatory T-cells and CD4 (+)\/CD8 (+) ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 26, 586\u2013591 (2013).","journal-title":"Pigment Cell Melanoma Res"},{"key":"BFsrep36360_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn, J. G. et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129, 2220\u20132232 (2009).","journal-title":"J Invest Dermatol"},{"key":"BFsrep36360_CR9","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.4049\/jimmunol.175.12.8327","volume":"175","author":"S Hayer","year":"2005","unstructured":"Hayer, S. et al. Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic mice. J Immunol 175, 8327\u20138336 (2005).","journal-title":"J Immunol"},{"key":"BFsrep36360_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.immunol.21.120601.141107","volume":"21","author":"TK Starr","year":"2003","unstructured":"Starr, T. K., Jameson, S. C. & Hogquist, K. A. Positive and negative selection of T cells. Annu Rev Immunol 21, 139\u2013176 (2003).","journal-title":"Annu Rev Immunol"},{"key":"BFsrep36360_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nri1707","volume":"5","author":"KA Hogquist","year":"2005","unstructured":"Hogquist, K. A., Baldwin, T. A. & Jameson, S. C. Central tolerance: learning self-control in the thymus. Nat Rev Immunol 5, 772\u2013782 (2005).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep36360_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.immuni.2006.06.009","volume":"25","author":"D Zehn","year":"2006","unstructured":"Zehn, D. & Bevan, M. J. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25, 261\u2013270 (2006).","journal-title":"Immunity"},{"key":"BFsrep36360_CR13","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.4049\/jimmunol.1500082","volume":"194","author":"BD Coder","year":"2015","unstructured":"Coder, B. D., Wang, H., Ruan, L. & Su, D. M. Thymic involution perturbs negative selection leading to autoreactive T cells that induce chronic inflammation. J Immunol 194, 5825\u20135837 (2015).","journal-title":"J Immunol"},{"key":"BFsrep36360_CR14","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.154.8.3961","volume":"154","author":"Y Kawakami","year":"1995","unstructured":"Kawakami, Y. et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154, 3961\u20133968 (1995).","journal-title":"J Immunol"},{"key":"BFsrep36360_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(94)91709-4","volume":"344","author":"YH Song","year":"1994","unstructured":"Song, Y. H. et al. The role of tyrosinase in autoimmune vitiligo. Lancet 344, 1049\u20131052 (1994).","journal-title":"Lancet"},{"key":"BFsrep36360_CR16","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.4049\/jimmunol.160.4.1750","volume":"160","author":"D Valmori","year":"1998","unstructured":"Valmori, D. et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A\/MART-1 immunodominant peptide analogues. J Immunol 160, 1750\u20131758 (1998).","journal-title":"J Immunol"},{"key":"BFsrep36360_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1046\/j.1523-1747.2003.12413.x","volume":"121","author":"RL Mandelcorn-Monson","year":"2003","unstructured":"Mandelcorn-Monson, R. L. et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA\/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 121, 550\u2013556 (2003).","journal-title":"J Invest Dermatol"},{"key":"BFsrep36360_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1046\/j.1523-1747.2001.01408.x","volume":"117","author":"B Palermo","year":"2001","unstructured":"Palermo, B. et al. Specific cytotoxic T lymphocyte responses against Melan-A\/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex\/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117, 326\u2013332 (2001).","journal-title":"J Invest Dermatol"},{"key":"BFsrep36360_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1046\/j.1523-1747.2001.01363.x","volume":"116","author":"KS Lang","year":"2001","unstructured":"Lang, K. S. et al. HLA-A2 restricted, melanocyte-specific CD8 (+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA\/MART1. J Invest Dermatol 116, 891\u2013897 (2001).","journal-title":"J Invest Dermatol"},{"key":"BFsrep36360_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1365-2133.2001.03952.x","volume":"144","author":"K Jimbow","year":"2001","unstructured":"Jimbow, K., Chen, H., Park, J. S. & Thomas, P. D. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol 144, 55\u201365 (2001).","journal-title":"Br J Dermatol"},{"key":"BFsrep36360_CR21","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/jid.2008.31","volume":"128","author":"S Adams","year":"2008","unstructured":"Adams, S. et al. Lack of functionally active Melan-A (26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients. J Invest Dermatol 128, 1977\u20131980 (2008).","journal-title":"J Invest Dermatol"},{"key":"BFsrep36360_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1468-3083.2006.01899.x","volume":"21","author":"JB Liu","year":"2007","unstructured":"Liu, J. B. et al. Association of vitiligo with HLA-A2: a meta-analysis. J Eur Acad Dermatol Venereol 21, 205\u2013213 (2007).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"BFsrep36360_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/jid.2011.240","volume":"132","author":"A Singh","year":"2012","unstructured":"Singh, A. et al. HLA alleles and amino-acid signatures of the peptide-binding pockets of HLA molecules in vitiligo. J Invest Dermatol 132, 124\u2013134 (2012).","journal-title":"J Invest Dermatol"},{"key":"BFsrep36360_CR24","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1046\/j.1365-2133.1998.02503.x","volume":"139","author":"EH Kemp","year":"1998","unstructured":"Kemp, E. H., Waterman, E. A., Gawkrodger, D. J., Watson, P. F. & Weetman, A. P. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 139, 798\u2013805 (1998).","journal-title":"Br J Dermatol"},{"key":"BFsrep36360_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1365-2249.1997.4781381.x","volume":"109","author":"EH Kemp","year":"1997","unstructured":"Kemp, E. H., Gawkrodger, D. J., Watson, P. F. & Weetman, A. P. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 109, 495\u2013500 (1997).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep36360_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1600-0625.2010.01181.x","volume":"20","author":"EH Kemp","year":"2011","unstructured":"Kemp, E. H. et al. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp Dermatol 20, 35\u201340 (2011).","journal-title":"Exp Dermatol"},{"key":"BFsrep36360_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/jid.2010.341","volume":"131","author":"Q Li","year":"2011","unstructured":"Li, Q. et al. Vitiligo autoantigen VIT75 is identified as lamin A in vitiligo by serological proteome analysis based on mass spectrometry. J Invest Dermatol 131, 727\u2013734 (2011).","journal-title":"J Invest Dermatol"},{"key":"BFsrep36360_CR28","doi-asserted-by":"publisher","first-page":"16060","DOI":"10.4238\/2015.December.7.19","volume":"14","author":"MC Zhu","year":"2015","unstructured":"Zhu, M. C., Liu, C. G., Wang, D. X. & Zhan, Z. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo. Genet Mol Res 14, 16060\u201316073 (2015).","journal-title":"Genet Mol Res"},{"key":"BFsrep36360_CR29","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","volume":"188","author":"GS Ogg","year":"1998","unstructured":"Ogg, G. S., Rod Dunbar, P., Romero, P., Chen, J. L. & Cerundolo, V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188, 1203\u20131208 (1998).","journal-title":"J Exp Med"},{"key":"BFsrep36360_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nature16962","volume":"530","author":"X Clemente-Casares","year":"2016","unstructured":"Clemente-Casares, X. et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530, 434\u2013440 (2016).","journal-title":"Nature"},{"key":"BFsrep36360_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.4161\/onci.19856","volume":"1","author":"YD Mahnke","year":"2012","unstructured":"Mahnke, Y. D. et al. Human melanoma-specific CD8 (+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology 1, 467\u2013530 (2012).","journal-title":"Oncoimmunology"},{"key":"BFsrep36360_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/exd.12581","volume":"24","author":"M Nieda","year":"2015","unstructured":"Nieda, M., Terunuma, H., Eiraku, Y., Deng, X. & Nicol, A. J. Effective induction of melanoma-antigen-specific CD8+ T cells via Vgamma9gammadeltaT cell expansion by CD56 (high+) Interferon-alpha-induced dendritic cells. Exp Dermatol 24, 35\u201341 (2015).","journal-title":"Exp Dermatol"},{"key":"BFsrep36360_CR33","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99, 16168\u201316173 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep36360_CR34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00262-011-1011-9","volume":"60","author":"J Yuan","year":"2011","unstructured":"Yuan, J. et al. CTLA-4 blockade increases antigen-specific CD8 (+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 60, 1137\u20131146 (2011).","journal-title":"Cancer Immunol Immunother"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep36360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36360","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:00:19Z","timestamp":1672884019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep36360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,21]]}},"alternative-id":["BFsrep36360"],"URL":"https:\/\/doi.org\/10.1038\/srep36360","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]},"assertion":[{"value":"1 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36360"}}